Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Thoracic 2Head & Neck 2Gastrointestinal 1Breast 1

Conditions

Brain Neoplasms 3

Interventions

Temozolomide 623Radiotherapy 411Bevacizumab 257Magnetic Resonance Spectroscopy 227Cyclophosphamide 179Radiosurgery 163Carboplatin 160Etoposide 132Radiation 129Vincristine 115Irinotecan 115Cisplatin 103Filgrastim 100Specimen Handling 90Nivolumab 88pembrolizumab 84Surgical Procedures, Operative 83Lomustine 83Topotecan 73Doxorubicin 61Melphalan 59Carmustine 57Radiotherapy, Intensity-Modulated 56sargramostim 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 51Chemotherapy, Adjuvant 51Blood Specimen Collection 51Erlotinib Hydrochloride 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
5-fluoropentyl-2-methylmalonic acid × CNS × Clear all
NCT00696943 2013-02-15

18F ML-10 for Early Detection of Response of Brain Metastases to SRS

Aposense Ltd.

Phase 2 Terminated
1 enrolled
CNS

Brain Neoplasms

NCT00791063 2013-02-13

18F ML-10 for Early Detection of Response of Brain Metastases to WBRT

Aposense Ltd.

Phase 2 Completed
10 enrolled
CNS

Brain Neoplasms

NCT00805636 2010-05-12

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Aposense Ltd.

Phase 2 Unknown
30 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡